Chapter: ECG Interpretation of QT Prolongation  

1. Justify the pharmacist’s role in interpreting ECGs.
2. Evaluate and interpret normal and abnormal waveforms and intervals on an ECG.
3. Measure and calculate the QT/corrected QT (QTc) interval using a 12-lead ECG.
4. Given a patient case and 12-lead ECG, analyze factors that influence the accuracy and reliability of the heart rate QTc.
5. Given a patient case, analyze risk factors for QT prolongation.
6. Given a patient case, provide recommendations for the management of QT prolongation. 

Case Series: Atrial Fibrillation Clinics

1. Justify the role of the pharmacist in the multidisciplinary team-based care for patients with atrial fibrillation.
2. Apply optimization of antiarrhythmic medication therapy management based on patientspecific factors.
3. Apply optimization of anticoagulant medication therapy management based on patientspecific factors.
4. Apply comprehensive medication management strategies to provide individualized care of patients with atrial fibrillation. 

Chapter: Ventricular Tachycardia

1. Identify the mechanism and type of ventricular tachycardias (VTs).
2. Recommend treatment options for the acute management of ventricular tachycardia.
3. Evaluate treatment options for the long-term management of ventricular tachycardia.
4. Distinguish the characteristics of select rare VT conditions and commonly used medical therapy. 

Chapter: Antiarrhythmic Medications vs. Ablation

1. Distinguish patients who are ideal candidates for early rhythm control.
2. Evaluate the risks and benefits of strategies to maintain normal sinus rhythm in patients with atrial fibrillation.
3. Develop a treatment plan for a patient who has undergone surgical or catheter ablation. 

Chapter: Cardiac Wearables and Self-Monitoring Devices

1. Identify available cardiac devices and sensors and the roles they play in preventing and/or managing cardiovascular disease states.
2. Evaluate clinical outcomes and treatment implications of cardiac wearables when screening for or managing preexisting atrial fibrillation.
3. Distinguish benefits and challenges with direct-to-consumer cardiac wearables.
4. Justify the role of home international normalized ratio monitoring for patients on chronic warfarin therapy.  

Chapter: Risk Modification for Atrial Fibrillation

1. Distinguish the differences between the lifestyle and risk factor modification (LRFM) recommendations of the previous and current atrial fibrillation (AF) guidelines.
2. Assess the risk for developing AF based on current modifiable and nonmodifiable risk factors.
3. Detect the presence of AF based on clinical evaluation and available screening tools.
4. Design an appropriate LRFM care plan when treating patients at risk for or diagnosed with AF.
5. Evaluate the risk for stroke and bleeding in patients with AF using validated risk stratification tools. 

Chapter: Antithrombotic Therapy for Valvular Heart Disease

1. Analyze the associated thrombotic risks associated with valvular heart disease (VHD) repair and replacement options.
2. Develop a pharmacologic treatment plan for a variety of patient subsets and situations after VHD correction interventions that optimizes the use of guideline-directed medical therapy.
3. Justify the pharmacist’s role in anticoagulation stewardship in patients with VHD. 

Case Series: Left Ventricular Thrombus

1. Assess risk factors for developing left ventricular (LV) thrombus.
2. Develop a patient care plan for preventing or treating LV thrombus.
3. Evaluate the use of a direct oral anticoagulant compared with warfarin in the treatment of LV thrombus.
4. Analyze the role of dual antiplatelet therapy and fibrinolytics for the treatment and prevention of LV thrombus. 

Recorded Webcast: Management of Supraventricular Tachycardias

1. Distinguish between the various dysrhythmias that are classified as supraventricular tachycardias (SVTs).
2. Determine available pharmacologic agents for treating patients with SVT.
3. Develop individualized treatment plans for patients with SVT.